SARS-CoV-2 viral shedding and transmission dynamics : implications of WHO COVID-19 discharge guidelines

This work was supported through the Alliance for Accelerating Excellence in Science in Africa (AESA), a funding, agenda-setting, programme management initiative of the African Academy of Sciences (AAS), the African- Union Development Agency (AUDA-NEPAD), founding and funding global partners and through a resolution of the summit of African Union Heads of Governments.The evolving nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and discharge guidelines. Since the identification of the first COVID-19 cases in November 2019, the World Health Organization (WHO) has played a crucial role in tackling the country-level pandemic preparedness and patient management protocols. Among others, the WHO provided a guideline on the clinical management of COVID-19 patients according to which patients can be released from isolation centers on the 10th day following clinical symptom manifestation, with a minimum of 72 additional hours following the resolution of symptoms. However, emerging direct evidence indicating the possibility of viral shedding 14 days after the onset of symptoms called for evaluation of the current WHO discharge recommendations. In this review article, we carried out comprehensive literature analysis of viral shedding with specific focus on the duration of viral shedding and infectivity in asymptomatic and symptomatic (mild, moderate, and severe forms) COVID-19 patients. Our literature search indicates that even though, there are specific instances where the current protocols may not be applicable ( such as in immune-compromised patients there is no strong evidence to contradict the current WHO discharge criteria.Publisher PDFPeer reviewe

Biomimetic biohybrid nanofibers containing Bovine Serum Albumin as a bioactive moiety for wound dressing

For the first time, a biohybrid nanofibrous wound dressing is developed via green electrospinning of a blend solution of bovine serum albumin (BSA) (1 and 3 wt.%) and polycaprolactone (PCL). In such a system, the components are miscible and interact through hydrogen bonding between the carbonyl group of PCL and the amine group of BSA, as verified by ATR-FTIR. As a result, the biohybrid nanofibers show a superior elastic modulus and elongation (300% and 58%, respectively) compared with the neat PCL nanofibers. The included protein induces a hydrophilicity effect to the PCL nanofibers, notably at the higher BSA content (3 wt.%). In contrast to the neat nanofibers, the biohybrid ones are bioactive and encourage formation of biominerals (made of amorphous calcium carbonate) on the surface, after immersion in simulated body fluid (SBF). Based on the WST-8 cell viability tests, NIH3T3 fibroblast cells were seen to properly interact with the biohybrid mats and to proliferate in their proximity. SEM images show that the cells largely adhere onto such nanofibers even more than they do on the neat ones and adopt a flattened and stretched shape. In addition, the Live/Dead assay and Phalloidin/DAPI staining assay confirm large cell viability and normal cell morphology on the biohybrid nanofiber mats after 4 days incubation. Taken together, BSA/PCL nanofibers are able to offer optimum mechanical properties (elasticity) as well as mineralization which can potentially stimulate the wound healing process, and can be considered a suitable candidate for wound dressing applications

SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines

The evolving nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and discharge guidelines. Since the identification of the first COVID-19 cases in November 2019, the World Health Organization (WHO) has played a crucial role in tackling the country-level pandemic preparedness and patient management protocols. Among others, the WHO provided a guideline on the clinical management of COVID-19 patients according to which patients can be released from isolation centers on the 10th day following clinical symptom manifestation, with a minimum of 72 additional hours following the resolution of symptoms. However, emerging direct evidence indicating the possibility of viral shedding 14 days after the onset of symptoms called for evaluation of the current WHO discharge recommendations. In this review article, we carried out comprehensive literature analysis of viral shedding with specific focus on the duration of viral shedding and infectivity in asymptomatic and symptomatic (mild, moderate, and severe forms) COVID-19 patients. Our literature search indicates that even though, there are specific instances where the current protocols may not be applicable ( such as in immune-compromised patients there is no strong evidence to contradict the current WHO discharge criteria

Scientific, sustainability and regulatory challenges of cultured meat

Producing meat without the drawbacks of conventional animal agriculture would greatly contribute to future food and nutrition security. This Review Article covers biological, technological, regulatory and consumer acceptance challenges in this developing field of biotechnology. Cellular agriculture is an emerging branch of biotechnology that aims to address issues associated with the environmental impact, animal welfare and sustainability challenges of conventional animal farming for meat production. Cultured meat can be produced by applying current cell culture practices and biomanufacturing methods and utilizing mammalian cell lines and cell and gene therapy products to generate tissue or nutritional proteins for human consumption. However, significant improvements and modifications are needed for the process to be cost efficient and robust enough to be brought to production at scale for food supply. Here, we review the scientific and social challenges in transforming cultured meat into a viable commercial option, covering aspects from cell selection and medium optimization to biomaterials, tissue engineering, regulation and consumer acceptance

Electrospinning of hydrogels for biomedical applications

The field of biomedical applications for hydrogels requires the development of nanostructures with specific controlled diameter and mechanical properties. Nanofibers are ideally candidates for these advanced requirements, and one of the easiest techniques that can produce one-dimensional nanostructured materials in fibrous form is the electrospinning. This technique provides extremely thin fibres with controlled diameter, highly porous microstructure with interconnected pores; extremely versatile allowing the use of various polymers for tailoring various applications requirements and it is a simple cost-effective method on preparation of scaffolds. In this section, we will discuss recent and specific applications with a focus on their mechanisms. As such, we conclude this section with a discussion on perspectives and future possibilities on this field.ye

Tunable biomaterials for myocardial tissue regeneration: promising new strategies for advanced biointerface control and improved therapeutic outcomes

Myocardial scaffold characteristics including mechanical property, pore size/porosity, immunomodulation, bioactivity, electroconductivity, injectability and thickness is reviewed and strategies to control each of them is discussed in details</jats:p

Analyzing polymeric nanofibrous scaffold performances in diabetic animal models for translational chronic wound healing research

AbstractTissue-engineered scaffolds for skin wound healing have undergone tremendous progress since the advent of autologous skin grafts or autografts. The recognition that a three-dimensional (3D) scaffold more closely mimics the biochemical-mechanical milieu of wounds and advancing knowledge of cell biology has led to the next-generation of engineered biopolymeric nanoscaffolds. These can pave the way towards personalized wound care as they can address multiple requirements of skin physiology. A unifying approach is required for translational success of scaffolds, involving clinicians, biologists, and chemists. Following in vitro testing using cell lines, pre-clinical studies on animal models is the next crucial step towards scaffold clinical translation. Often, success noted in these studies does not replicate in human patients due to the heterogeneous nature of wound conditions and causes that cannot be found in a single animal model. In this review, we give an overview of the status of pre-clinical mice models for types 1 and 2 diabetic wound healing and relate this to studies conducted with polymeric nanoscaffolds. Translational shortcomings of these models are analyzed where they fail to provide a good replica of human conditions. Categorization and use of more sophisticated models, which can closely mimic the diabetic features, are addressed for translational use of nanoscaffolds.</jats:p

Mimicking growth factors: role of small molecule scaffold additives in promoting tissue regeneration and repair

Scaffold loaded with small molecules mimicking the action of growth factors for tissue repair.</p